NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced the launch of the nCounter® ADC Development Panel, a specialized gene expression tool for use in the rapidly expanding field of Antibody Drug Conjugates (ADCs).
You Might Also Like
Mission Bio’s New Translocation Analysis Offers Insights into Critical Safety Assessment for Gene-Edited Cell Products
PerkinElmer’s Horizon Discovery CHOSOURCE Cell Line Supports Trinomab Biotech’s Development of the World-First, Tetanus Toxin mAb Drug for Clinical Trials
